Transglutaminase 2 promotes PDGF-mediated activation of PDGFR/Akt1 and β-catenin signaling in vascular smooth muscle cells and supports neointima formation

Journal of Vascular Research

Volumn 51, Issue 6, 2014, Pages 418-428

  Nurminskaya, Maria ^a   Beazley, Kelly E ^a   Smith, Elizabeth P ^a   Belkin, Alexey M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Akt1; Neointima; Platelet derived growth factor; Transglutaminase 2; Vascular smooth muscle cells; Catenin

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN AKT1; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN KINASE B; UNCLASSIFIED DRUG; AKT1 PROTEIN, MOUSE; CTNNB1 PROTEIN, MOUSE; GUANINE NUCLEOTIDE BINDING PROTEIN; PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL OCCLUSION; CAROTID ARTERY LIGATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY BLOOD VESSEL; EX VIVO STUDY; GENE DELETION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEOINTIMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; AGONISTS; ANIMAL; C57BL MOUSE; CAROTID STENOSIS; CELL CULTURE; CELL MOTION; CORONARY STENOSIS; DEFICIENCY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SMOOTH MUSCLE CELL; TIME FACTOR;

ANIMALS; BETA CATENIN; CAROTID STENOSIS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CORONARY STENOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSGLUTAMINASES;

EID: 84924260639     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000369461     Document Type: Article

References (63)

1. Sarkar K, Sharma SK, Sachdeva R, Romeo F, Garza L, Mehta JL: Coronary artery restenosis: vascular biology and emerging therapeutic strategies. Expert Rev Cardiovasc Ther 2006; 4: 543-556.
2. Subbotin VM: Analysis of arterial intimal hyperplasia: review and hypothesis. Theor Biol Med Model 2007; 4: 41-49.
3. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R: Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510.
4. Zheng, Q, Liu S, Song Z: Mechanism of arterial remodeling in chronic allograft vasculopathy. Front Med 2011; 5: 248-253.
5. Chaabane C, Otsuka F, Virmani R, Bochaton-Piallat M-L: Biological responses in stented arteries. Cardiovasc Res 2013; 99: 353-363.
6. Seedial SM, Ghosh S, Saunders RS, Suwanabol PA, Shi X, Liu B, Kent KC: Local drug delivery to prevent restenosis. J Vasc Surg 2013; 57: 1403-1414.
7. Zhang LN, Parkinson JF, Haskell C, Wang YX: Mechanisms of intimal hyperplasia learned from a murine carotid artery ligation model. Curr Vasc Pharmacol 2008; 6: 37-43.
8. Inoue T, Node K: Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J 2009; 73: 615-621.
9. Majesky MW, Dong XR, Regan JN, Hoglund VJ: Vascular smooth muscle progenitor cells: building and repairing blood vessels. Circ Res 2011; 108: 365-377.
10. O'Brien ER, Ma X, Simar T, Pourdjabbar A, Hibbert B: Pathogenesis of neointima formation following vascular injury. Cardiovasc Hematol Disord Drug Targets 2011; 11: 30-39.
11. Goel SA, Guo LM, Liu B, Kent KC: Mechanism of post-intervention arterial remodeling. Cardiovasc Res 2012; 96: 363-371.
12. London GM, Marchais SJ, Guerin AP, Metivier F: Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005; 14: 525-531.
13. Johnson RC, Leopold JA, Loscalzo J: Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006; 99: 1044-1059.
14. Sane DC, Kontos JL, Greenberg CS: Roles of transglutaminases in vascular and cardiac diseases. Front Biosci 2007; 12: 2530-2545.
15. Bakker EN, Pistea A, Vanbavel E: Transglutaminase in vascular biology: relevance for vascular remodeling and atherosclerosis. J Vasc Res 2008; 22: 271-278.
16. Haroon ZA, Wannenburg T, Gupta M, Greenberg CS, Wallin R, Sane DC: Localization of tissue transglutaminase in human carotid and coronary artery atherosclerosis: implications for plaque stability and progression. Lab Invest 2001; 81: 83-93.
17. Cho BR, Kim MK, Suh DH, Hahn JH, Lee BG, Choi YC, Kwon TJ, Kim SY, Kim DJ: Increased tissue transglutaminase expression in human atherosclerotic coronary arteries. Coron Artery Dis 2008; 19: 459-468.
18. Matlung HL, van Bavel E, van den Akker J, de Vries CJ, Bakker EN: Role of trans-glutaminases in cuff-induced atherosclerotic lesion formation in femoral arteries of ApoE3 Leiden mice. Atherosclerosis 2010; 213: 77-84.
19. Faverman L, Mikhaylova L, Malmquist J, Nurminskaya M: Extracellular transglutaminase 2 activates β-catenin signaling in calcifying vascular smooth muscle cells. FEBS Lett 2008; 582: 1552-1557.
20. Johnson KA, Polewski M, Terkeltaub RA: Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ Res 2008; 102: 529-537.
21. Beazley KE, Banyard D, Lima F, Deasey SC, Nurminsky DI, Konoplyannikov M, Nurminskaya MV: Transglutaminase inhibitors attenuate vascular calcification in a preclinical model. Arterioscler Thromb Vasc Biol 2013; 33: 43-51.
22. Bakker EN, Buus CL, Spaan JAE, Perree J, Ganga A, Rolf TM, Sorop O, Bramsen LH, Mulvany MJ, van Bavel E: Small artery remodeling depends on tissue-Type transglutaminase. Circ Res 2004; 96: 119-126.
23. Pistea A, Bakker EN, Spaan JA, Hardeman MR, van Rooijen N, van Bavel E: Small artery remodeling and erythrocyte deformability in L-NAME-induced hypertension: role of transglutaminases. J Vasc Res 2008; 45: 271-278.
24. van den Akker J, VanBavel E, van Geel R, Matlung HL, Guvenc Tuna B, Janssen GM, van Veelen PA, Boelens WC, De Mey JG, Bakker EN: The redox state of transglutaminase 2 controls arterial remodeling. PLoS One 2011; 6:e23067.
25. Watts SW, Priestley JR, Thompson JM: Serotonylation of vascular proteins important to contraction. PLoS One 2009; 4:e5682.
26. Johnson KB, Thompson JM, Watts SW: Modification of proteins by norepinephrine is important for vascular contraction. Front Physiol 2010; 131: 1-8.
27. Engholm M, Eftekhari A, Chwatko G, Bald E, Mulvany MJ: Effect of cystamine on blood pressure and vascular characteristics in spontaneously hypertensive rats. J Vasc Res 2011; 48: 476-484.
28. Wei L, Warburton RR, Preston IR, Roberts KE, Comhair SA, Erzurum SC, Hill NS, Fanburg BL: Serotonylated fibronectin is elevated in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2012; 302:L1273-L1279.
29. Huelsz-Prince G, Belkin AM, VanBavel E, Bakker EN: Activation of extracellular transglutaminase 2 by mechanical force in the arterial wall. J Vasc Res 2013; 50: 383-395.
30. DiRaimondo TR, Klock C, Warburton R, Herrera Z, Penumatsa K, Toksoz D, Hill N, Khosla C, Fanburg B: Elevated transglutaminase 2 activity is associated with hypoxiainduced experimental pulmonary hypertension in mice. ACS Chem Biol 2014; 9: 266-275.
31. Santhanam L, Tuday EC, Webb AK, Dowzicky P, Kim JH, Oh YJ, Sikka G, Kuo M, Halushka MK, Macgregor AM, Dunn J, Gutbrod S, Yin D, Shoukas A, Nyhan D, Flavahan NA, Belkin AM, Berkowitz DE: Decreased S-nitrosylation of tissue transglutaminase contributes to age-related increases in vascular stiffness. Circ Res 2010; 107: 117-125.
32. Jung SM, Jandu S, Steppan J, Belkin A, An SS, Pak A, Choi EY, Nyhan D, Butlin M, Viegas K, Avolio A, Berkowitz DE, Santhanam L: Increased tissue transglutaminase activity contributes to central vascular stiffness in eNOS knockout mice. Am J Physiol Heart Circ Physiol 2013; 305:H803-H810.
33. Steppan J, Sikka G, Jandu S, Barodka V, Halushka MK, Flavahan NA, Belkin AM, Nyhan D, Butlin M, Avolio A, Berkowitz DE, Santhanam L: Exercise, vascular stiffness, and tissue transglutaminase. J Am Heart Assoc 2014; 3:e00599.
34. Belkin AM: Extracellular TG2: emerging functions and regulation. FEBS J 2011; 278: 4704-4716.
35. Nurminskaya MV, Belkin AM: Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol 2012; 294: 1-97.
36. Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GV, Mehta K: Transglutaminase regulation of cell function. Physiol Rev 2014; 94: 383-417.
37. Zemskov EA, Loukinova E, Mikhailenko I, Coleman RA, Strickland DK, Belkin AM: Regulation of platelet-derived growth factor receptor function by integrin-Associated cell surface transglutaminase. J Biol Chem 2009; 284: 16693-16703.
38. Zemskov EA, Mikhailenko I, Smith EP, Belkin AM: Tissue transglutaminase promotes PDGF/PDGFR-mediated signaling and responses in vascular smooth muscle cells. J Cell Physiol 2012; 227: 2089-2096.
39. Heldin C-H, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-1316.
40. Raines EW: PDGF and cardiovascular disease. Cytokine Growth Factor Rev 2004; 15: 237-254.
41. Owens GK: Molecular control of vascular smooth muscle cell differentiation and phenotypic plasticity. Novartis Found Symp 2007; 283: 174-191.
42. Andrae J, Gallini R, Betsholtz C: Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-1312.
43. Levitzki A: PDGF receptor kinase inhibitors for the treatment of restenosis. Cardovasc Res 2005; 65: 581-586.
44. Quasnichka H, Slater SC, Beeching CA, Boehm M, Sala-Newby GB, George SJ: Regulation of smooth muscle cell proliferation by β-catenin/T-cell factor signaling involves modulation of cyclin D1 and p21 expression. Circ Res 2006; 99: 1329-1337.
45. Nunes RO, Schmidt M, Dueck G, Baarsma H, Halayko AJ, Kerstjens HA, Meurs H, Gosens R: GSK-3/β-catenin signaling axis in airway smooth muscle: role in mitogenic signaling. Am J Physiol Lung Cell Mol Physiol 2008; 294: L1110-L1118.
46. Tsaousi A, Williams H, Lyon CA, Taylor V, Swain A, Johnson JL, George SJ: Wnt4/ β-catenin signaling induces VSMC proliferation and is associated with intimal thickening. Circ Res 2011; 108: 427-436.
47. Beazley KE, Deasey S, Lima F, Nurminskaya MV: Transglutaminase 2-mediated activation of β-catenin signaling has a critical role in warfarin-induced vascular calcification. Arterioscler Thromb Vasc Biol 2012; 32: 123-130.
48. Beazley KE, Zhang T, Lima F, Pozharskaya T, Niger C, Tzitzikov E, Azimzadeh AM, Nurminskaya M: Implication for transglutaminase 2-mediated activation of β-catenin signaling in neointimal vascular smooth muscle cells in chronic cardiac allograft rejection. J Heart Lung Transplant 2012; 31: 1009-1017.
49. Condello S, Cao L, Matei D: Tissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism. FASEB J 2013; 27: 3100-3112.
50. Deasey S, Nurminsky D, Shanmugasundaram S, Lima F, Nurminskaya M: Transglutaminase 2 as a novel activator of LRP6/β-catenin signaling. Cell Signal 2013; 25: 2646-2651.
51. Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham RM: Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 2001; 276: 20673-20678.
52. Habeler W, Pouillot S, Plancheron A, Puceat M, Peschanski M, Monville C: An in vitro beating heart model for long-Term assessment of experimental therapeutics. Cardiovasc Res 2009; 81: 253-259.
53. Kumar A, Lindner V: Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 1997; 17: 2238-2244.
54. Ross R: The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 1971; 50: 172-186.
55. Belkin AM, Klimanskaya IV, Lukashev ME, Lilley K, Critchley DR, Koteliansky VE: A novel phosphoglucomutase-related protein is concentrated in adherens junctions of muscle and nonmuscle cells. J Cell Sci 1994; 107: 159-173.
56. Reusch HP, Zimmermann S, Schaefer M, Paul M, Moelling K: Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 2001; 236: 33630-33637.
57. Yang L, Lin C, Liu ZR: P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from β-catenin. Cell 2006; 127: 139-155.
58. Ren S, Johnson BG, Kida Y, Ip C, Davidson KC, Lin SL, Kobayashi A, Lang RA, Hadjantonakis AK, Moon RT, Duffield JS: LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci U S A 2013; 110: 1440-1445.
59. Couffinhal T, Dufourcq P, Duplaa C: β-Catenin nuclear activation: common pathway between Wnt and growth factor signaling in vascular smooth muscle cell proliferation?. Circ Res 2006; 99: 1287-1289.
60. Morrison JA, Klingelhutz AJ, Raab-Traub N: Epstein-Barr virus latent membrane protein 2A activates β-catenin signaling in epithelial cells. J Virol 2003; 77: 12276-12284.
61. Gantner BN, Jin H, Qian F, Hay N, He B, Ye RD: The Akt1 isoform is required for optimal IFN-? transcription through direct phosphorylation of β-catenin. J Immunol 2012; 189: 3104-3112.
62. Sharma M, Chuang WW, Sun Z: Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem 2002; 277: 30935-30941.
63. Atkins RJ, Dimou J, Paradiso L, Morokoff AP, Kaye AH, Drummond KJ, Hovens CM: Regulation of glycogen synthase 3-kinase beta (GSK-3β) by the Akt pathway in gliomas. J Clin Neurosci 2012; 19: 1558-1563.